CD16 antigen has been proposed as a marker of osteoclast precursors in psoriatic arthritis or in Multiple Myeloma: CD14+CD16+ cells were, in fact, more prone to differentiate toward osteoclasts, at least in these two diseases [9,20]. This evidence concerns the gene FCGR3A and psoriatic arthritis.